Market Research Logo

Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016

Infantile Spasm (West Syndrome) - Pipeline Review, H2 2016

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Infantile Spasm (West Syndrome) – Pipeline Review, H2 2016, provides an overview of the Infantile Spasm (West Syndrome) (Central Nervous System) pipeline landscape.

Infantile spasms are a type of epilepsy with a characteristic age of onset (typical age when seizures start), pattern of seizures and electroencephalogram (EEG). Symptoms include typical pattern is of a sudden flexion (bending forward) in a tonic (stiffening) fashion of the body, arms and legs. Sometimes, the episodes are different, with the arms and legs being flung outwards (these are called ‘extensor’ spasms). Causes include central nervous system infections, abnormal brain development or injury, genetic abnormalities (Down syndrome, Miller-Dieker syndrome) and metabolic disorders (mitochondrial diseases, phenylketonuria, and hypoglycemia). Treatment includes antiepileptic medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Infantile Spasm (West Syndrome) – Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide also reviews of key players involved in therapeutic development for Infantile Spasm (West Syndrome) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 2, 2 and 4 respectively.Infantile Spasm (West Syndrome).

Infantile Spasm (West Syndrome) (Central Nervous System) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Infantile Spasm (West Syndrome) (Central Nervous System).
  • The pipeline guide reviews pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Infantile Spasm (West Syndrome) (Central Nervous System) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Infantile Spasm (West Syndrome) (Central Nervous System)
Reasons to buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Infantile Spasm (West Syndrome) (Central Nervous System).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Infantile Spasm (West Syndrome) (Central Nervous System) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.


Introduction
Global Markets Direct Report Coverage
Infantile Spasm (West Syndrome) Overview
Therapeutics Development
Pipeline Products for Infantile Spasm (West Syndrome) - Overview
Infantile Spasm (West Syndrome) - Therapeutics under Development by Companies
Infantile Spasm (West Syndrome) - Pipeline Products Glance
Clinical Stage Products
Early Stage Products
Infantile Spasm (West Syndrome) - Products under Development by Companies
Infantile Spasm (West Syndrome) - Companies Involved in Therapeutics Development
Anavex Life Sciences Corp
Catalyst Pharmaceuticals Inc
GW Pharmaceuticals Plc
INSYS Therapeutics Inc
Novartis AG
Retrophin Inc
Infantile Spasm (West Syndrome) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
ANAVEX-273 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AVL-5189 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cannabidiol - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cosyntropin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cosyntropin ER - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CPP-115 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JBPOS-0101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Infantile Spasm (West Syndrome) - Dormant Projects
Infantile Spasm (West Syndrome) - Product Development Milestones
Featured News & Press Releases
Sep 19, 2016: Catalyst Pharmaceuticals Announces Publication of CPP-115 Clinical Efficacy Data for Infantile Spasms in Epilepsy & Behavior Case Reports
Jun 22, 2016: Anavex Announces U.S. FDA Orphan Drug Designation for ANAVEX 2-73 for Treatment of Infantile Spasms
Jun 21, 2016: GW Pharmaceuticals Announces New Planned Epidiolex (Cannabidiol or CBD) Development Program in Infantile Spasms (IS)
May 18, 2016: Anavex Announces Positive Preclinical Data for ANAVEX 2-73 in Infantile Spasms
Feb 09, 2016: Insys Therapeutics Enrolls First Patient in Phase II Study for the Treatment of Infantile Spasms Using Pharmaceutical CBD
Dec 16, 2015: Catalyst Pharmaceuticals Announces Top-Line Results in Phase 1(b) Trial of CPP-115
Aug 04, 2015: Insys Therapeutics Receives FDA Orphan Drug Designation for Its Pharmaceutical Cannabidiol for the Treatment of Infantile Spasms
Nov 24, 2014: Catalyst Pharmaceuticals Announces Notice of Allowance of U.S. Patent Application for the Reduction or Elimination of Visual Field Defects by Treating Patients With CPP-115
Sep 02, 2014: Catalyst Pharmaceutical Partners Initiates Phase 1(b) Safety and Tolerance Study for CPP-115
Nov 18, 2013: Catalyst Pharmaceutical Partners Announces Publication of Preclinical Proof-of-Principle of CPP-115 Efficacy in Suppressing Infantile Spasms in Epilepsia
Feb 13, 2012: Catalyst Receives Orphan Medicinal Product Designation In EU For CPP-115 To Treat West Syndrome
Jan 31, 2012: Catalyst Pharmaceutical Partners To Present CPP-115 Progress At 2012 Epilepsy Pipeline Update Conference
Dec 15, 2011: Catalyst Announces Scientific Paper Regarding CPP-115 For Treatment Of Cocaine Addiction Accepted For Publication In Journal Of Medicinal Chemistry
Dec 13, 2011: Catalyst Starts Phase Ia Safety Study For CPP-115
Dec 02, 2011: Catalyst To Present Data On CPP-115 At American Epilepsy Society's 65th Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
List of Tables
Number of Products under Development for Infantile Spasm (West Syndrome), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Comparative Analysis by Early Stage Development, H2 2016
Products under Development by Companies, H2 2016
Infantile Spasm (West Syndrome) - Pipeline by Anavex Life Sciences Corp, H2 2016
Infantile Spasm (West Syndrome) - Pipeline by Catalyst Pharmaceuticals Inc, H2 2016
Infantile Spasm (West Syndrome) - Pipeline by GW Pharmaceuticals Plc, H2 2016
Infantile Spasm (West Syndrome) - Pipeline by INSYS Therapeutics Inc, H2 2016
Infantile Spasm (West Syndrome) - Pipeline by Novartis AG, H2 2016
Infantile Spasm (West Syndrome) - Pipeline by Retrophin Inc, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Stage and Target, H2 2016
Number of Products by Stage and Mechanism of Action, H2 2016
Number of Products by Stage and Route of Administration, H2 2016
Number of Products by Stage and Molecule Type, H2 2016
Infantile Spasm (West Syndrome) - Dormant Projects, H2 2016
List of Figures
Number of Products under Development for Infantile Spasm (West Syndrome), H2 2016
Number of Products under Development by Companies, H2 2016
Comparative Analysis by Clinical Stage Development, H2 2016
Assessment by Monotherapy Products, H2 2016
Number of Products by Top 10 Targets, H2 2016
Number of Products by Stage and Top 10 Targets, H2 2016
Number of Products by Top 10 Mechanism of Actions, H2 2016
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016
Number of Products by Routes of Administration, H2 2016
Number of Products by Stage and Routes of Administration, H2 2016
Number of Products by Molecule Types, H2 2016
Number of Products by Stage and Molecule Types, H2 2016

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report